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INTRODUCTION
The COVID-19 pandemic has had a major impact on cancer 
care due to diversion of healthcare resources to treat COVID-19 
patients and changes in healthcare-seeking behavior of patients 
with symptoms of cancer.1, 2 This has led to severe delays in 
the diagnosis and treatment of cancer patients worldwide.3, 4 
Reported increases in the risk of surgical treatment linked to 
COVID-19 infection and lack of normal perioperative health-
care facilities prompted an increased use of nonoperative 
treatments.5,6
Early reports suggested that cancer patients are at greater risk 
of contracting COVID-19 and that they have worse COVID-19 
outcomes.7–10 It was estimated that up to a quarter of patients 
with perioperative COVID-19 infection undergoing any type of 
surgery would die, with four-fifths of these deaths due to pul-
monary complications, further contributing to a reluctance to 
offer elective surgery when it might reasonably be delayed to a 
safer time.11, 12
There is little evidence on the safety of colorectal cancer 
(CRC) surgery during the COVID-19 pandemic. A few rela-
tively small studies have suggested that it may be possible to 
operate safely.13–16 Measures used to reduce the risks related 
to perioperative COVID-19 for patients undergoing planned 
cancer surgery include preoperative isolation and COVID-19 
swab testing.
In the English National Health Service (NHS), one approach 
to reduce the risk of patients acquiring COVID-19 while in hos-
pital has been the separation of hospitals into “cold” sites used 
for patients free of COVID-19 and “hot” sites used for all other 
patients.17, 18 Preoperative isolation and COVID-19 swab test-
ing were used in patients having surgery in “cold” and “hot” 
sites to reduce the risk of community acquired infection. The 
effectiveness of separating CRC services in this way is uncertain. 
Also, it is often not feasible to redirect patients who present 
with CRC as an emergency to a specific site for urgent lifesaving 
intervention.
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Objective: To compare the management and outcomes of colorectal cancer (CRC) patients during the first 2 months of the 
COVID-19 pandemic with the preceding 6 months.
Background: The pandemic has affected the diagnosis and treatment of CRC patients worldwide. Little is known about the safety 
of major resection and whether creating “cold” sites (COVID-free hospitals) is effective.
Methods: A national study in England used administrative hospital data for 14,930 CRC patients undergoing surgery between 
October 1, 2019, and May 31, 2020. Mortality of CRC resection was compared before and after March 23, 2020 (“lockdown” start).
Results: The number of elective CRC procedures dropped sharply during the pandemic (from average 386 to 214 per week), 
whereas emergency procedures were hardly affected (from 88 to 84 per week). There was little change in characteristics of surgical 
patients during the pandemic. Laparoscopic surgery decreased from 62.5% to 35.9% for elective and from 17.7% to 9.7% for emer-
gency resections. Surgical mortality increased slightly (from 0.9% to 1.2%, P = 0.06) after elective and markedly (from 5.6% to 8.9%, 
P = 0.003) after emergency resections. The observed increase in mortality during the first phase of the pandemic was similar in “cold” 
and “hot” sites (P > 0.5 elective and emergency procedures).
Conclusions: The pandemic resulted in a 50% reduction in elective CRC procedures during the initial surge and a substantial 
increase in mortality after emergency resection. There was no evidence that surgery in COVID-free “cold” sites led to better outcomes 
in the first 2 months.
Keywords: COVID-19, colorectal cancer, surgical mortality
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The aim of this study was to quantify changes in the surgical 
management and surgical mortality of CRC patients during the 
initial peak of the COVID-19 pandemic period and to assess 
whether the separation of hospitals into “hot” and “cold” sites 
was effective in reducing the COVID-19 risk in the first wave of 
the pandemic. Our study included a highly representative pop-
ulation as we studied all patients admitted for CRC surgery in 
the NHS, the publicly funded national healthcare system that 
provides more than 95% of healthcare in England, including 
NHS patients treated in the independent sector.19
METHODS
Data Source
The Hospital Episode Statistics (HES) database contains 
records of all admissions to NHS hospitals and of NHS patients 
treated in independent sector hospitals in England.20 These 
records include diagnostic information coded according to the 
International Classification of Diseases, 10th revision (ICD-
10).21 Procedure information is coded according to the Office 
of Population Censuses and Surveys Classification of Surgical 
Operations and Procedures, 4th Revision (OPCS-4).22
Study Population
All patients identified in HES as having been admitted with CRC 
(ICD-10: “C18,” “C19,” or “C20”) who had a surgical CRC proce-
dure (major resection, stoma or stent, OPCS-4: “H04-H11,” “H29,” 
“H33,” “H40,” “H411,” “H414,” “H471,” “H479,” “X141,” 
“X142,” “X143,” “X148,” and “X149”) between October 1, 2019, 
and May 31, 2020, were included. For each patient, the earliest sur-
gical procedure was used. Patients who underwent a stoma or stent 
procedure in addition to a major resection were classified as having 
had a major resection. When multiple resections occurred on the 
same date, the first listed resection was used.
COVID-19 Pandemic Period
Patients were considered to have been treated during the initial 
wave of the COVID-19 pandemic if their surgical procedure was 
on or after March 23, 2020. This date corresponds to the start 
of the “lockdown” period, during which the UK government 
banned all nonessential travel and contact with people outside 
one’s home, and almost all schools and businesses were closed.23
Patient Characteristics
Four-character ICD-10 codes provided the detailed tumor site, 
and four-character OPCS-4 codes provided the type of surgical 
procedure. HES records include the mode of admission (“elec-
tive” and “emergency”), and we assumed that procedures in 
an elective admission were elective procedures and those in an 
emergency admission were emergency procedures. Diagnoses 
of metastatic cancer in the 6 months before and 1 month after 
CRC surgery (ICD-10: “C780-C784,” “C786,” “C787,” “C79”) 
were used to identify patients with stage IV disease. The Royal 
College of Surgeons Charlson score was used to identify comor-
bidities based on diagnostic information in the operative admis-
sion and admissions in the preceding 6 months.24 The area of 
residence, defined according to the Office for National Statistics 
with a typical population of about 1500 people, was used to 
capture socioeconomic deprivation according to the national 
Index of Multiple Deprivation Quintiles (IMDQ).25
Mortality and Other Surgical Outcomes
Outcomes analyses were restricted to patients undergoing 
a major resection (ie, patients undergoing a stoma or stent 
procedure only were excluded). The main outcome was death 
in hospital within 30 days of CRC resection. Patients with a 
recorded critical care episode during their admission were con-
sidered to have been admitted to critical care. Length of stay 
(LOS) was the number of days between the date of operative 
procedure and discharge from hospital. Unplanned readmis-
sions and reoperations within 30 days of a resection were iden-
tified in HES using methods described previously.26
Identification of COVID-19 Status
Either of the ICD-10 codes for confirmed or suspected COVID-
19 infection (“U071,” “U072”) within the operative admission 
were used to indicate COVID-19 infection. It was not possi-
ble to differentiate between hospital-acquired infections and 
patients admitted with preexisting COVID-19 infection.
Identification of “Hot” and “Cold” Hospital Sites
Information on “hot” and “cold” hospital sites came from a 
mapping exercise performed by the National Bowel Cancer 
Audit in June 2020.27 Clinical leads in each NHS hospital 
were asked for the location of all NHS and independent-sector 
COVID-19 “cold” sites available to their hospital in mid-April 
2020. “Hot” and “cold” site information was available for 146 
of the 148 NHS hospitals that provide CRC surgery in England. 
A further six independent-sector “cold” site hospitals were iden-
tified in the data as providing CRC surgery only since the start 
of the pandemic. For the two NHS hospitals that did not pro-
vide information on “hot” and “cold” sites, we relied on the 
information in the data on independent sector “cold” sites. This 
identified one of these hospitals as having access to a “cold” site.
Statistical Analysis
Chi-squared tests were used to compare mortality after major 
resection before or during the pandemic. Multivariable logistic 
regression was used to model, separately for elective and emer-
gency resections, the difference in surgical mortality before and 
during the COVID-19 pandemic, adjusted for case-mix factors 
(age, sex, stage IV disease, number of comorbidities, and socio-
economic deprivation), using robust standard errors to deal 
with clustering of data within hospitals. We assessed interac-
tions between period of treatment (before or during the pan-
demic) and type of site (“hot” and “cold” site) using Wald tests. 
Complete case analyses were used because only 2% of patients 
undergoing CRC resection were missing data on any of the case-
mix factors.
A sensitivity analysis was carried out in which a random 
intercept for hospital was included in each adjusted logistic 
regression model to reflect a variation in outcomes between hos-
pitals. The adjusted results were little changed.
RESULTS
Eleven thousand seven hundred three patients with CRC under-
went surgery in the English National Health Service immedi-
ately before the COVID-19 pandemic and 3227 during the early 
COVID-19 pandemic period.
The number of patients who underwent elective CRC sur-
gery dropped sharply at the end of March 2020, decreasing by 
almost a half over a period of 3 weeks from on average 386 
procedures a week in the 6 weeks before the pandemic to 214 
procedures a week from week 3 of the pandemic (Figure 1). The 
number of emergency procedures dropped slightly at the end 
of March 2020 but returned to similar levels as before the pan-
demic within around 3 weeks from on average 88 procedures 
a week in the 6 weeks before the pandemic to 84 procedures a 
week from week 3 of the pandemic.
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The reduction in elective procedures was predominantly in 
“hot” sites (Figure 1). Some independent sector hospitals started 
to function as “cold” sites for elective services from the end of 
March 2020 and contributed almost 50% of the “cold” site 
provision from mid-April 2020. Approximately one-sixth of 
all elective CRC surgery was provided in an independent sector 
“cold” site during the early pandemic period.
Patient and Surgical Characteristics Before and During the 
COVID-19 Pandemic
There were only small differences in the characteristics of 
patients having elective surgery during the COVID-19 pan-
demic compared to before (Table 1). During the pandemic, these 
patients were on average slightly younger and had slightly fewer 
comorbidities. There was a small shift from elective anterior 
resections (from 31.0% before to 27.0% during the pandemic 
period) toward Hartmann’s procedures (from 5.8% to 11.1%). 
There was a substantial drop in the proportion of elective resec-
tions carried out laparoscopically (from 62.5% to 35.9%) and a 
small decrease in the proportion of patients who were recorded 
as admitted to critical care (from 7.8% to 5.1%).
There was relatively little change in the characteristics of 
patients undergoing emergency procedures during the pandemic 
(Table 1). There was a decrease in the proportion of resections 
carried out laparoscopically (from 17.7% to 9.7%), and a slight 
decrease in the proportion of patients recorded as admitted to 
critical care (from 12.9% to 11.4%).
Mortality After Major CRC Resection
Table 2 shows that the overall 30-day inpatient mortality after 
an elective resection was slightly increased during the COVID-19 
pandemic period (1.2%; 95% CI: 0.8% to 1.8%) compared 
with before (0.9%; 95% CI: 0.7% to 1.2%). After adjustment 
for age, sex, stage IV cancer, comorbidities, and socioeconomic 
deprivation, there was no statistical evidence of increased 
elective mortality (adjusted OR 1.54 [95% CI: 0.98 to 2.43], 
P = 0.063). Small, nonsignificant increases in 30-day inpatient 
mortality were seen both in “hot” sites (from 1.0% to 1.4%) 
and in “cold” sites (from 0.7% to 0.9%), and there was no sta-
tistical evidence of a difference in these increases between “hot” 
and “cold” sites (P for interaction 0.855).
The overall 30-day inpatient mortality after emergency resec-
tion increased markedly during the pandemic (8.9%; 95% CI: 
6.6% to 11.7%) compared with before (5.6%; 95% CI: 4.5% 
to 6.9%) and this difference remained statistically significant 
after risk adjustment (adjusted OR 1.74 [95% CI: 1.21 to 2.50], 
P = 0.003). The 30-day inpatient mortality increased both in 
“hot” sites (from 5.6% to 8.8%) and “cold” sites (from 5.7% 
FIGURE 1. Number of CRC procedures performed per week in relation to the start of the COVID-19 pandemic (March 23, 2020: week 0) by “hot” and “cold” 
sites. A, Elective procedures and (B) emergency procedures. CRC indicates colorectal cancer; NHS, National Health Service.
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to 9.8%), and again there was no statistical evidence of a dif-
ference in these increases between “hot” and “cold” sites (P for 
interaction 0.544).
Other Surgical Outcomes
There were only minor, nonsignificant differences in unplanned 
readmissions and reoperations before and during the pan-
demic, regardless of urgency (Table 3; P always > 0.3). Hospital 
stays of over 14 days were much more frequent before the 
pandemic than during, particularly for elective patients (from 
13.5% to 8.4%) but also for emergency patients (from 32.2% 
to 26.4%).
Sensitivity Analysis
A random intercept for hospital was included in each adjusted 
logistic regression model to reflect a variation in outcomes 
between hospitals. The adjusted results were not materially 
changed.
Patients With a Recorded COVID-19 Diagnosis
Overall, 144 patients had a confirmed or suspected COVID-19 
diagnosis in their surgical record during the study period 
(Table 1). A small proportion had a recorded COVID-19 diag-
nosis before the pandemic period (0.4% of elective patients and 
0.5% of emergency patients), and almost all of these had CRC 
surgery in March 2020. The proportion of patients with periop-
erative COVID-19 infection was considerably higher during the 
pandemic (1.9% elective and 6.3% emergency patients) and 
was higher in “hot” sites (2.5% elective and 6.6% emergency 
patients) than in “cold” sites (1.0% elective and 4.1% emer-
gency patients) during the pandemic.
Of the patients with a confirmed or suspected COVID-19 
diagnosis, 119 (82.6%) underwent major resection. Mortality 
in these patients was high, with one in seven patients who had 
elective surgery (13.9%; 95% CI: 7.2% to 23.5%) and one in 
four patients who had emergency surgery (25.0%; 95% CI: 
12.7% to 41.2%) dying in hospital within 30 days (Table 4). 
Thirty-day reoperation rates and length of hospital stay were 
also considerably increased in these patients.
TABLE 1.
Characteristics of 14,930 CRC Patients Undergoing Surgery Immediately Before and During the COVID-19 Pandemic Period in the 
English National Health Service
 
Elective Surgery Emergency Surgery
Before Pandemic During Pandemic Before Pandemic During Pandemic
N % N % N % N %
Total 9424  2427  2279  800  
Age group (y) <50 611 6.5 176 7.6 242 10.6 78 9.8
50–59 1315 14.0 345 14.9 326 14.3 115 14.4
60–74 4487 47.7 1110 47.9 890 39.1 305 38.2
75–84 2446 26.0 594 25.7 590 25.9 215 26.9
≥85 542 5.8 90 3.9 228 10.0 86 10.8
Missing 23 (0.2) 112 (4.6) 3 (0.1) 1 (0.1)
Gender Male 5327 56.5 1358 56.0 1259 55.2 435 54.4
Female 4097 43.5 1069 44.0 1020 44.8 365 45.6
Tumor site Caucus/appendix/ascending colon 2563 27.2 671 27.6 623 27.3 221 27.6
Hepatic flexure 404 4.3 102 4.2 108 4.7 33 4.1
Transverse colon 607 6.4 168 6.9 191 8.4 75 9.4
Splenic flexure/descending colon 447 4.7 101 4.2 232 10.2 87 10.9
Sigmoid colon 1907 20.2 450 18.5 576 25.3 202 25.2
Rectosigmoid 684 7.3 192 7.9 166 7.3 61 7.6
Rectum 2731 29.0 711 29.3 326 14.3 98 12.3
Not classified 81 0.9 32 1.3 57 2.5 23 2.9
Stage IV CRC 743 7.9 182 7.5 682 29.9 219 27.4
Comorbidities 0 4973 52.8 1348 55.5 1132 49.7 400 50.0
1 2861 30.4 739 30.4 727 31.9 245 30.6
≥2 1590 16.9 340 14.0 420 18.4 155 19.4
Surgical procedure Right hemi/transverse colectomy 3572 37.9 940 38.7 842 36.9 304 38.0
Left hemicolectomy 367 3.9 77 3.2 53 2.3 10 1.3
Sigmoid colectomy 363 3.9 75 3.1 34 1.5 7 0.9
Total/subtotal colectomy 299 3.2 81 3.3 110 4.8 37 4.6
Anterior resection 2920 31.0 656 27.0 78 3.4 20 2.5
APER/pelvic exenteration 711 7.5 168 6.9 15 0.7 4 0.5
Hartmann’s 542 5.8 270 11.1 361 15.8 144 18.0
Stoma 546 5.8 131 5.4 588 25.8 182 22.8




1 (most deprived) 1419 15.2 302 13.1 402 17.8 117 14.8
2 1673 18.0 411 17.9 404 17.9 143 18.1
3 1886 20.2 475 20.7 488 21.6 182 23.0
4 2177 23.4 581 25.3 456 20.2 184 23.2
5 (most affluent) 2165 23.2 531 23.1 506 22.4 166 21.0
Missing 104 (1.1) 127 (5.2) 253 (1.0) 8 (1.0)
COVID-19 ICD-10 code recorded during operative admission 36 0.4 47 1.9 11 0.5 50 6.3
Total patients undergoing a major resection 8774  2267  1493  526  
Laparoscopic surgery performed 5485 62.5 814 35.9 264 17.7 51 9.7
Critical care admission 687 7.8 116 5.1 192 12.9 60 11.4
APER, abdominoperineal excision of rectum; CRC, colorectal cancer; ICD-10, International Classification of Diseases, 10th revision; IMDQ, index of multiple deprivation quintiles.




In the first 2 months of the COVID-19 pandemic period in the 
English NHS, the number of patients undergoing elective CRC 
surgery halved, whereas the number undergoing emergency 
CRC surgery remained static. There was little change in the 
characteristics of patients treated during the pandemic, both for 
elective and emergency surgery, but there was a clear change in 
surgical practice with a sharp drop in the use of the laparoscopic 
approach and a shift from anterior resection with colorectal 
anastomosis for rectal cancer toward Hartmann’s procedure 
with colostomy.
The onset of the pandemic was also associated with an 
increase in mortality after major CRC resection, both in elec-
tive and emergency surgery. A key finding of our study is 
that this increase in surgical mortality did not appear to be 
mitigated by treating patients in designated “cold” sites at 
this stage of the pandemic. This is in contrast to an inter-
national cohort study that demonstrated that the provision 
of COVID-19 “cold” sites reduces the risk of hospital-ac-
quired COVID-19 infection, pulmonary complications, and 
mortality.28
Mortality after CRC resection was very high in CRC patients 
who had a confirmed or suspected perioperative COVID-19 
diagnosis with about one in seven dying after an elective and 
one in four after an emergency CRC resection.
Limitations
The first limitation of this study was that detailed information 
on cancer stage, disease severity, or symptoms that may war-
rant earlier surgery, such as bleeding or obstruction, was not 
available. However, we did adjust for stage IV disease, age, sex, 
comorbidities, and socioeconomic deprivation. In line with 
other studies, we found little change in any of these characteris-
tics during the pandemic.16 Prioritization for surgery of patients 
with more advanced disease and delayed presentation of emer-
gency patients is likely to explain some of the increased mortal-
ity during the pandemic, but data were not available on nodal 
status or tumor size to be able to explore this.
Second, it is very likely that we under-report patients who 
had a COVID-19 diagnosis due to lack of available testing 
at the time and the high proportion of asymptomatic cases. 
Consequently, the main comparison of our study is between 
patients operated before and during the COVID-19 pan-
demic period rather than between patients with and without a 
COVID-19 diagnosis.
TABLE 2.
30-day In-patient Mortality After Major CRC Resection Immediately Before and During the COVID-19 Pandemic Period
Elective Surgery
 Before Pandemic During Pandemic
During Versus Before Pandemic
N = 10,823 patients with complete data on age, sex, stage IV cancer,  
comorbidities, and socioeconomic deprivation
 N % 95% CI N % 95% CI Crude Odds Ratio Adjusted Odds Ratio 95% CI P P Interaction
All sites 8774 0.9 0.7–1.2 2267 1.2 0.8–1.8 1.35 1.54 0.98–2.43 0.063  
Hot sites 7221 1.0 0.8–1.2 1411 1.4 0.9–2.2 1.47 1.65 0.97–2.82 0.067 0.855
Cold sites 1553 0.7 0.4–1.3 856 0.9 0.4–1.8 1.29 1.49 0.57–3.88 0.413  
Emergency Surgery
 
Before Pandemic During Pandemic
During Versus Before Pandemic
N = 1994 patients with complete data on age, sex, stage IV cancer,  
comorbidities, and socioeconomic deprivation
 N % 95% CI N % 95% CI Crude Odds Ratio Adjusted Odds Ratio 95% CI P P Interaction
All sites 1493 5.6 4.5–6.9 526 8.9 6.6–11.7 1.67 1.74 1.21–2.50 0.003  
Hot sites 1232 5.6 4.4–7.0 444 8.8 6.3–11.8 1.65 1.67 1.10–2.52 0.015 0.554
Cold sites 261 5.7 3.3–9.3 82 9.8 4.3–18.3 1.76 2.19 1.02–4.71 0.045  
CI, confidence intervals; CRC, colorectal cancer.
TABLE 3.
30-day Unplanned Readmission, Reoperation, and Length of 
Hospital Stay After Major CRC Resection Immediately Before 
and During the COVID-19 Pandemic Period
 Before Pandemic During Pandemic  
 Number % 95% CI Number % 95% CI P
Elective Surgery
 Total 8774   2267    
 30-d readmission 895 10.2 9.6–10.9 240 10.6 9.3–11.9 0.661
 30-d reoperation 728 8.3 7.7–8.9 170 7.5 6.4–8.6 0.322
 LOS >14 d 1188 13.5 12.8–14.3 191 8.4 7.3–9.6 <0.001
Emergency Surgery
 Total 1493   526    
 30-d readmission 163 10.9 9.4–12.6 62 11.8 9.2–14.9 0.572
 30-d reoperation 165 11.1 9.6–12.8 60 11.4 8.8–14.4 0.858
 LOS >14 d 481 32.2 29.9–34.7 139 26.4 22.7–30.4 0.014
CI, confidence intervals; CRC, colorectal cancer.
TABLE 4.
 30-day In-patient Mortality, Unplanned Readmission, Reoperation, 
and Length of Hospital Stay After Major CRC Resection in 119 
Patients With a Confirmed or Suspected COVID-19 Diagnosis*
Elective Surgery
 Number % 95% CI
Total 79   
 30-d in-patient mortality 11 13.9 7.2–23.5
 30-d reoperation 21 26.6 17.3–37.7
 Median (IQR) length of stay (d)  17 10–32
Elective Surgery
 Number % 95% CI
Total 40   
 30-d in-patient mortality 10 25.0 12.7–41.2
 30-d reoperation 7 17.5 7.4–32.8
 Median (IQR) length of stay (d)  20 11–32
*30-day readmission is not presented for patients with a confirmed or suspected COVID-19 diagno-
sis because such a high proportion died or were still in hospital within 30 days of surgery.
CI, confidence intervals; CRC, colorectal cancer; IQR, interquartile range.
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Third, there was no generally accepted definition of a “cold” 
site at the time of our study, which may have diluted the dif-
ferences in outcomes between “hot” and “cold” sites. Further 
details on the characteristics of the “hot” and “cold” sites would 
have allowed a more robust comparison between them. “Cold” 
sites were being set up during the study period, and their defin-
ing characteristics may have developed over time. In most cases, 
they will eventually have included rapid access to testing for 
patients and hospital staff, separate clinical teams, geographical 
separation of COVID and non-COVID services and dedicated 
access to cold support services in patient transport, diagnostics, 
radiology, and critical care.29 Other preventative measures to 
protect patients against perioperative COVID-19, including pre-
operative COVID-19 testing, and presurgery household isola-
tion may not have always been fully implemented, although they 
were advocated during the study period. All patients included 
in the study were NHS patients, whether they were treated in 
“hot” or “cold” sites, and other than the type of site for their 
surgical treatment, there is no reason to expect differences in 
their cancer care.
Fourth, it is likely that critical care admissions were under-re-
corded in HES data. Previous studies have estimated that around 
a third of patients go to critical care during their CRC surgery 
admission, whereas we estimated this to be around 10%.30 It 
is unlikely, however, that the under-reporting of critical care 
admissions would differ before and during the pandemic and 
our study can therefore provide an estimate of the relative 
reduction in access.
Fifth, information on cause of death was unavailable. This 
may have helped to understand the reasons for the increase in 
mortality during the pandemic.
Finally, in this study, the start of the pandemic was defined 
as March 23, 2020, the date of the UK “lockdown” period. As 
demonstrated in the study, this also coincides with the start 
of severe disruption to CRC services in the United Kingdom. 
However, it is known that the first cases of COVID-19 in the 
populations were before this.31,32 It was not possible to carry out 
additional analyses to explore the effect of changing this start 
date because shifting the date earlier would make the number of 
deaths in cold sites before the pandemic too small to be able to 
make reliable comparisons.
Findings on the Disruption of CRC Surgery
Limited access to elective surgery has been widely recognized 
during the COVID-19 pandemic with one study reporting that 
about one-third of CRC surgeries were canceled or postponed 
in the 12 weeks of peak disruption.1 Our national data showed 
an even greater reduction in the overall numbers of patients 
undergoing CRC surgery during the first months of the pan-
demic. However, in line with other studies, we found that the 
number of patients undergoing emergency treatment was hardly 
affected.33–35
Our study indicates that there was sufficient capacity, in 
terms of access to hospital beds, emergency theater provision, 
and perioperative care either in “hot” or “cold” sites, to ensure 
that most patients with an emergency presentation of CRC 
were relatively protected and could proceed to surgery without 
significant delay, which is especially important for the manage-
ment of patients with an acute condition. However, capacity 
for elective CRC surgery halved, which was driven predomi-
nantly by the diversion of healthcare resources and staff toward 
the management of COVID-19 patients and measures put in 
place to prevent COVID-19 transmission. It is unlikely that 
this diversion from elective care will be as prominent in future 
resurgences of the pandemic, given that in many countries 
COVID-19 vaccination of vulnerable groups will reduce the 
pressure on hospital capacity.36 Recent modeling also suggests 
that preoperative vaccination of all elective surgical patients 
may greatly reduce the risks of hospital-acquired postoperative 
COVID-19 infection.37
Initial national guidelines issued for the United Kingdom 
indicated that all non-emergency CRC surgery (ie, treatment not 
required within 72 hours) may be delayed by up to 12 weeks 
without major prognostic implications, and this guidance may 
have further contributed to these reductions.38 However, subse-
quent evidence has suggested that a 12-week delay might reduce 
overall survival for CRC patients by up to 19%.39
Temporizing treatment strategies, such as short-course radio-
therapy with prolonged wait to surgery, were used to minimize 
the effect of delaying CRC resection.17 Patients with locally 
advanced rectal cancer who might previously have been con-
sidered for pelvic exenteration were deferred because of the 
resource intensity of this procedure and the expectation that 
outcomes would be negatively affected in the event of acquiring 
nosocomial COVID-19 infection during a more prolonged hos-
pital stay. Similarly, patients with metastatic disease may have 
been offered stenting and systemic anticancer therapy or best 
supportive care rather than palliative resection of a symptom-
atic primary tumor.40, 41
In addition to a reduction in the number of surgical proce-
dures, there was a substantial decrease in laparoscopic access 
and an increase in stoma rates. These changes followed initial 
national professional guidance advocating against laparoscopy 
and in favor of risk-averse surgery to reduce critical care admis-
sions for anastomotic complications.42 Recent evidence suggests 
that adequate personal protective equipment, and closed-loop 
insufflation systems or filtration devices, may facilitate safe 
laparoscopic procedures during the COVID-19 pandemic. 
Laparoscopic surgery is therefore unlikely to be reduced during 
later waves of COVID-19, given its advantages in reduced length 
of stay and lower risk of pulmonary sequela.15, 43
Findings on the Effectiveness of Measures to Mitigate 
COVID-19 Risk
Our study found that despite measures to mitigate COVID-19 
risk in CRC patients undergoing surgery, such as the introduc-
tion of COVID-19 surgical “cold” sites, surgical mortality was 
higher during the first 2 months of the pandemic period, espe-
cially in patients who needed emergency treatment. This finding 
corresponds to earlier findings in much smaller studies in the 
United Kingdom and Spain.33, 34
This study did not find evidence of a difference in surgical 
mortality between patients treated in “hot” and “cold” sites. 
Further data will be needed to adequately power such compar-
isons. Other studies have demonstrated that the provision of 
COVID-19 “cold” sites reduces the risk of hospital-acquired 
COVID-19 infection and pulmonary complications.15, 28, 44–46
It is likely that the increase in mortality after CRC resections 
during the COVID-19 pandemic is related to several factors. First, 
our results confirm that COVID-19 infection greatly increased 
surgical mortality.11 However, COVID-19 infection itself can 
only explain a very small part of the observed increases in mor-
tality. Based on our findings, it can be estimated that approxi-
mately 20% of the patients who had emergency CRC resection 
needed to be infected to fully explain the observed increases 
in surgical mortality, whereas the population COVID-19 
infection level was about 0.25% in England at the time.47, 48 This 
very small contribution of COVID-19 infection is also one of the 
most likely explanations of our observation that the increases in 
mortality after CRC resections during the COVID-19 pandemic 
period were very similar in “hot” and “cold” sites.
Second, we only found small decreases in patients moving to 
critical care after an elective CRC resection during the pandemic. 
Although other studies have found larger reductions in critical 
care use for patients undergoing elective procedures,16 our find-
ing suggests that restricted access to critical care facilities can 
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only be a minor explanation for the observed increases in CRC 
surgical mortality.
Third, a further possible explanation for the increases in sur-
gical mortality during the pandemic is that operating with per-
sonal protection equipment caused visual, communication, and 
dexterity issues, which interfered with the quality of surgery.49 
However, there was no increase in the reoperation rate either 
for elective or for emergency CRC resections that would also 
have been expected if wearing personal protection equipment 
had affected the safety of surgery. Similarly, redeployment of 
theater staff and lack of specialized theater teams accustomed 
to working together may have been a contributor to the human 
factor aspects, especially in emergency surgery. It is also pos-
sible that the shift in where patients were treated during the 
pandemic was toward hospitals with a different quality of care, 
although the majority of surgeons operating in the independent 
sector in the United Kingdom are NHS surgeons who carry out 
both NHS and private work.
Fourth, reluctance of patients to access healthcare during the 
pandemic may have led to late presentation and an increase in 
nutritionally and physiologically decompensated patients pre-
senting for emergency surgery. And triage of elective patients 
based on clinical urgency is likely to have led to patients with 
more advanced disease undergoing resection during the pan-
demic. These factors may further explain some of the increased 
surgical mortality.
CONCLUSIONS
Surgical resection is the mainstay of treatment for non-metastatic 
CRC. We found a halving of elective CRC procedures and a sub-
stantial increase in surgical mortality during the first 2 months 
of the COVID-19 pandemic. Both are of significant concern for 
CRC patients and clinical services, demonstrating the impor-
tance of maintaining CRC services and minimizing surgical risk 
during further resurgences of the pandemic. The likelihood of 
such resurgences depends on the effectiveness of vaccination 
strategies and the emergence of new COVID-19 variants.
The concept of using safe “cold” surgical sites, and the strate-
gies needed to implement these, will need ongoing refinement to 
ensure implementation of maximum resilience for CRC surgery 
services during future waves of the COVID-19 pandemic.
The significantly worse outcomes during the pandemic can-
not be explained directly by COVID-19 infection. Further study 
will be needed to understand the most likely factors responsi-
ble for this marked deterioration but may include the negative 
impact of personal protection equipment and constrained the-
ater teams on surgeon performance, delayed clinical presenta-
tion and lack of safeguarding of the entire perioperative care 
pathway for high-risk CRC patients.
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